- |||||||||| Tafinlar (dabrafenib) / Novartis, Zelboraf (vemurafenib) / Roche
Journal: 7-dehydrocholesterol suppresses melanoma cell proliferation and invasion via Akt1/NF-κB signaling. (Pubmed Central) - Nov 18, 2020 Overall, the present results demonstrated that 7-DHC suppressed melanoma cell proliferation and invasion via the Akt1/NF-ĸB signaling pathway, and 7-DHC key target genes were negatively associated with the prognosis. These findings highlight the potential application of 7-DHC for the treatment of melanoma in the future.
- |||||||||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker: New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma. (Pubmed Central) - Nov 7, 2020 The emergence of invasive NPMs in patients treated with triple regimens with BRAF/mitogen-activated protein kinase kinase inhibitors and PD1/PDL1 inhibitors is at least unexpected and constitutes a therapeutic stalemate for the physician. Through this case report, we aim to increase awareness about the diagnosis and management of patients with NPM and to express our concerns regarding further management of NPMs in patients under triple combination treatment.
- |||||||||| Zelboraf (vemurafenib) / Roche
Journal: Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation. (Pubmed Central) - Nov 7, 2020 Compound 6a, merging the best inhibitory profile against the target kinases, showed anti-proliferative efficacy against the human melanoma cell lines A2058, expressing the BRAF V600D mutation, and WM266-4, expressing BRAF V600E. Significantly, it displayed also a highly synergistic profile when tested in combination with vemurafenib, thus proving its efficacy not only per se but even in a combination therapy, which is nowadays acknowledged as the cornerstone approach of the forthcoming tumour management.
- |||||||||| Journal: Identification and Tracking of Antiviral Drug Combinations. (Pubmed Central) - Nov 6, 2020
These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status.
- |||||||||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca, Innate, Zelboraf (vemurafenib) / Roche
[VIRTUAL] High Multiplex Immune Profiling of the Bone Marrow Tumor Microenvironment Identifies Prognostic Biomarkers in Hairy Cell Leukemia (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3730; This is the first study to provide a high multiplex analysis of HCL BM microenvironment demonstrating significant immune dysregulation of the BM that does not recover with therapy and identify biomarkers of response to standard of care CDA. Prospective application of these biomarkers will allow early identification and increased monitoring/treatment in patients at increased relapse risk post CDA treatment.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal, PD(L)-1 Biomarker, IO Biomarker: Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies. (Pubmed Central) - Nov 1, 2020 Furthermore, immune checkpoint PD-1 and CTLA4 inhibitors with favorable clinical outcomes in the treatment of cutaneous melanoma have increased recurrence-free survival and reduced metastatic spread in CM cases. The complex molecular mechanisms that contribute to the development of CM can be targeted both by molecular inhibitors of oncogenic pathways as well as immune checkpoint inhibitors in order to halt progression of the disease and increase survival.
- |||||||||| Zelboraf (vemurafenib) / Roche
Review, Journal: Photosensitivität unter Vemurafenib. (Pubmed Central) - Oct 30, 2020 The complex molecular mechanisms that contribute to the development of CM can be targeted both by molecular inhibitors of oncogenic pathways as well as immune checkpoint inhibitors in order to halt progression of the disease and increase survival. No abstract available
- |||||||||| Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date: BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia (clinicaltrials.gov) - Oct 29, 2020 P2, N=36, Active, not recruiting, Whether TT or CPI should be administered first to specific populations requires randomized prospective evaluation. Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
- |||||||||| Trial completion date, Trial primary completion date, Tumor mutational burden, BRCA Biomarker, MSi-H Biomarker, PARP Biomarker, PD(L)-1 Biomarker: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (clinicaltrials.gov) - Oct 23, 2020
P2, N=3279, Recruiting, Moreover, the response to vemurafenib is less and of shorter duration also due to rapidly acquired resistance, most likely by resorting to non-canonical growth signaling. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
- |||||||||| Zelboraf (vemurafenib) / Roche
[VIRTUAL] Erdheim–Chester disease: a single center experience () - Oct 21, 2020 - Abstract #EHOC2020EHOC_260; However, the mean age of our patients, who were American and French, were low. Evaluation of the expression levels of BRAFV600E was performed for three patients, but the results were negative.
- |||||||||| Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 19, 2020
P2a, N=658, Active, not recruiting, Altogether, our results support the development of ALK and RAF1 combined inhibition as a new therapeutic approach in ALK+ ALCL. Trial primary completion date: Sep 2020 --> Mar 2021
- |||||||||| erlotinib / Generic mfg.
Journal: Nevoid melanoma and eruptive nevi from erlotinib. (Pubmed Central) - Oct 15, 2020 We speculate that a similar mechanism may occur during treatment with EGFR inhibitors. Therefore, thorough skin examinations are essential for patients undergoing long term treatment with erlotinib.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] The role of immune checkpoint inhibitor as a single agent or combination therapy in advanced thyroid cancer () - Oct 14, 2020 - Abstract #SITC2020SITC_1240; No CR was reported, and the overall response rates (ORRs) varied from 9% (pembrolizumab monotherapy and nivolumab plus ipilimumab) to 64% (pembrolizumab plus lenvatinib) (figure 1a).1–4 In ATC, four studies have reported favorable outcomes in the context of dabrafenib and trametinib.5 The efficacy of spartalizumab, a PD1-inhibitor, was evaluated in a phase I/II trial, rendering an ORR of 19%, with 3 CRs (7%) and 5 PRs (12%) [6]...Landscape of combination checkpoint inhibition agents.Abbreviations: DTC, differentiated thyroid cancer; ATC, anaplastic thyroid cancer, MTC, medullary thyroid cancer; NIVO, nivolumab; IPI, ipilimumab; LENV, lenvatinib; ATEZO, atezolizumab; VEM, vemurafenib; COBI, cobimetinib, DAB, dabrafenib; TRAME, trametinib; PEM, pembrolizumab; DOXY, doxycycline; SBRT: Stereotactic radiation therapy...In particular, dual ICIs or combination of TKI and ICI can be developed as treatment options for ATC. Further large scale randomized prospective studies are required to establish ICIs as standard of care.
|